Inkretinbasierte Ko- und Triagonisten: Innovative Polypharmakologie zur Behandlung von Adipositas und Diabetes

Translated title of the contribution: Incretin-based co- and tri-agonists: Innovative polypharmacology for the treatment of obesity and diabetes

A. Harger, K. Stemmer, M. H. Tschöp, T. D. Müller

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Background: The worldwide rise in overweight and obesity is paralleled by an increasing prevalence of type-2 diabetes. Apart from bariatric surgery, treatment options to decrease body weight are often underwhelming. Innovative pharmacological options are required to cope with the global “diabesity” pandemic. Objectives: Particular novel pharmacological approaches are discussed, with a special focus on polyagonist-based pharmacotherapies. Materials and methods: Articles on co- and tri-agonists for the treatment of obesity and diabetes are presented and discussed. Results: Unimolecular peptides have been developed for the treatment of obesity and type-2 diabetes. These peptides activate the receptors of multiple hormones and bundle their positive effects in one single molecule. In preclinical studies, polyagonists targeting the receptors for glucagon-like peptide-1 (GLP-1), glucagon, or glucose-dependent insulinotropic peptide (GIP) were promising to reduce body weight and blood glucose. GLP-1-mediated delivery of the nuclear hormones estrogen or dexamethasone also yielded beneficial effects in preclinical studies of obesity. Conclusions: Polyagonists represent an innovative strategy for the development of novel pharmacotherapies to treat obesity and diabetes.

Translated title of the contributionIncretin-based co- and tri-agonists: Innovative polypharmacology for the treatment of obesity and diabetes
Original languageGerman
Pages (from-to)895-902
Number of pages8
JournalInternist
Volume60
Issue number9
DOIs
StatePublished - 1 Sep 2019

Fingerprint

Dive into the research topics of 'Incretin-based co- and tri-agonists: Innovative polypharmacology for the treatment of obesity and diabetes'. Together they form a unique fingerprint.

Cite this